Antegrin Expands Portfolio with Orally Available Integrin Antagonists

ST. LOUIS–(BUSINESS WIRE)–Antegrin has licensed a series of orally available integrin antagonists from Saint Louis University, for use in treating fibrosis.
Source: BusinessWire-Primary

Antegrin Expands Portfolio with Orally Available Integrin Antagonists